|
1
|
Patel SR, Vadhan-Raj S, Burgess MA, Plager
C, Papadopolous N, Jenkins J and Benjamin RS: Results of two
consecutive trials of dose-intensive chemotherapy with doxorubicin
and ifosfamide in patients with sarcomas. Am J Clin Oncol.
21:317–321. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lorigan P, Verweij J, Papai Z, et al:
European Organisation for Research and Treatment of Cancer Soft
Tissue and Bone Sarcoma Group Study: Phase III trial of two
investigational schedules of ifosfamide compared with standard-dose
doxorubicin in advanced or metastatic soft tissue sarcoma: A
European Organisation for Research and Treatment of Cancer Soft
Tissue and Bone Sarcoma Group Study. J Clin Oncol. 25:3144–3150.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pautier P, Floquet A, Penel N, et al:
Randomized multicenter and stratified phase II study of gemcitabine
alone versus gemcitabine and docetaxel in patients with metastatic
or relapsed leiomyosarcomas: a Federation Nationale des Centres de
Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM
study). Oncologist. 17:1213–1220. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maki RG, Wathen JK, Patel SR, et al:
Randomized phase II study of gemcitabine and docetaxel compared
with gemcitabine alone in patients with metastatic soft tissue
sarcomas: results of sarcoma alliance for research through
collaboration study 002 (corrected). J Clin Oncol. 25:2755–2763.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Merimsky O, Meller I, Flusser G, Kollender
Y, Issakov J, Weil-Ben-Arush M, Fenig E, Neuman G, Sapir D, Ariad
S, et al: Gemcitabine in soft tissue or bone sarcoma resistant to
standard chemotherapy: a phase II study. Cancer Chemother
Pharmacol. 45:177–181. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Svancarova L, Blay JY, Judson IR, et al:
Gemcitabine in advanced adult soft-tissue sarcomas. A phase II
study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J
Cancer. 38:556–559. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hensley ML, Maki R, Venkatraman E, Geller
G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R and
Spriggs DR: Gemcitabine and docetaxel in patients with unresectable
leiomyosarcoma: Results of a phase II trial. J Clin Oncol.
20:2824–2831. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hensley ML: Update on gemcitabine and
docetaxel combination therapy for primary and metastatic sarcomas.
Curr Opin Oncol. 22:356–361. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hensley ML, Blessing JA, Mannel R and Rose
PG: Fixed-dose rate gemcitabine plus docetaxel as first-line
therapy for metastatic uterine leiomyosarcoma: a Gynecologic
Oncology Group phase II trial. Gynecol Oncol. 109:329–334. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wist EA, Sommer HH, Ostenstad B, Risberg T
and Fjaestad K: Weekly one-hour paclitaxel as first-line
chemotherapy for metastatic breast cancer. Acta Oncol. 43:11–14.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sparano JA, Wang M, Martino S, Jones V,
Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC and Davidson
NE: Weekly paclitaxel in the adjuvant treatment of breast cancer. N
Engl J Med. 358:1663–1671. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kellokumpu-Lehtinen P, Tuunanen T, Asola
R, et al: Weekly paclitaxel - an effective treatment for advanced
breast cancer. Anticancer Res. 33:2623–2627. 2013.PubMed/NCBI
|
|
13
|
Trotti A, Colevas AD, Setser A, Rusch V,
Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and
Rubin P: CTCAE v3.0: development of a comprehensive grading system
for the adverse effects of cancer treatment. Semin Radiat Oncol.
13:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and
Verweij J: New response evaluation criteria in solid tumours:
revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Navid F, Willert JR, McCarville MB, Furman
W, Watkins A, Roberts W and Daw NC: Combination of gemcitabine and
docetaxel in the treatment of children and young adults with
refractory bone sarcoma. Cancer. 113:419–425. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Leu KM, Ostruszka LJ, Shewach D, Zalupski
M, Sondak V, Biermann JS, Lee JS, Couwlier C, Palazzolo K and Baker
LH: Laboratory and clinical evidence of synergistic cytotoxicity of
sequential treatment with gemcitabine followed by docetaxel in the
treatment of sarcoma. J Clin Oncol. 22:1706–1712. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sutton GP, Blessing JA, DeMars LR, Moore
D, Burke TW and Grendys EC: A phase II Gynecologic Oncology Group
trial of ifosfamide and mesna in advanced or recurrent
adenocarcinoma of the endometrium. Gynecol Oncol. 63:25–27. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Talbot SM, Keohan ML, Hesdorffer M, Orrico
R, Bagiella E, Troxel AB and Taub RN: A phase II trial of
temozolomide in patients with unresectable or metastatic soft
tissue sarcoma. Cancer. 98:1942–1946. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sanfilippo R, Grosso F, Jones RL, Banerjee
S, Pilotti S, D'Incalci M, Dei Tos AP, Raspagliesi F, Judson I and
Casali PG: Trabectedin in advanced uterine leiomyosarcomas: a
retrospective case series analysis from two reference centers.
Gynecol Oncol. 123:553–556. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
van der Graaf WT, Blay JY, Chawla SP, et
al: EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group:
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a
randomised, double-blind, placebo-controlled phase 3 trial. Lancet.
379:1879–1886. 2012. View Article : Google Scholar : PubMed/NCBI
|
